GlassScriptPhysician profile
Alison Joy Simpson
NPI 1306314026
$1,795.98
in general payments reported to CMS, 2019-2025
25 companies · $399 in 2025
The $399 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $103 · 2023: $484 · 2024: $810 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,692.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $241.96 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $204.10 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $147.18 | 2023-2024 | |
| Amgen INC. | $139.08 | 2022-2025 | Evenity, Prolia, Repatha |
| Janssen Pharmaceuticals, INC | $133.88 | 2023-2024 | Xarelto |
| Glaxosmithkline, LLC. | $132.62 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $123.45 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Neurocrine Biosciences, INC. | $71.79 | 2024 | Ingrezza |
| Alkermes, INC. | $69.30 | 2023-2025 | Aristada, Lybalvi |
| Abbott Laboratories | $64.36 | 2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.20 | 2023-2025 | Caplyta |
| Lilly USA, LLC | $59.65 | 2023-2024 | Jardiance, Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $51.78 | 2024 | |
| Vanda Pharmaceuticals INC. | $45.64 | 2023 | Fanapt, Hetlioz |
| Phathom Pharmaceuticals, INC. | $43.92 | 2024 | Voquezna |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $31.58 | 2024-2025 | Immunocap |
| Lundbeck LLC | $29.22 | 2025 | Rexulti |
| Inspire Medical Systems, INC. | $20.86 | 2025 | Inspire |
| Corium, LLC | $18.41 | 2023 | Azstarys |
| Alnylam Pharmaceuticals INC. | $18.41 | 2023 | Amvuttra |
| Sanofi-Aventis U.S. LLC | $18.41 | 2025 | |
| Dexcom, INC. | $17.21 | 2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.08 | 2024 | Xifaxan |
| Axsome Therapeutics, INC. | $16.06 | 2023 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $15.83 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.